LaDIY

LaDIY Healthcare Sdn Bhd (LaDIY) is an innovative medical device company that designs and develops novel diagnostic solutions and services, focusing on cancer diagnostics. LaDIY will enhance its value proposition to patients and stakeholders through further R&D of its current product technology platform to include a web based and mobile application. The company has plans to enter the diagnostic laboratory market to complement and enhance its product offering.

Campaign Closed

% of target	0 days left
Investors	0
Min Target	RM 1,000,000
Max Target	RM 2,000,000

Introduction

LaDIY aims to be a recognised global leader in delivering quality and comprehensive healthcare and medical solutions, to significantly improve the quality of life. We achieve our vision by providing innovative healthcare and medical solutions through the research and development of high quality, cost-effective products and services;

Detection of cervical cancer forms the focus of our initial product offering - Cervisafe. Our product addresses the aspects of privacy and convenience issues for women to get these tests done on a regular basis, which accounts for late detection or inadequate detection frequency.

What We Do

The Challenge

76%

Women in Malaysia at risk for cervical cancer (Female population aged >=15 years)

Key Statistics

Cervical cancer is the 4th most frequent cancer in women with an estimated 570,000 new cases in 2018 representing 6.6% of all female cancers (according to the World Health Organization);
Early detection, screening and vaccination can reduce the risk of getting the cancer by 70%.;
The current methods of detection are the Papanicolaou (Pap) tests and the more specific Human Papillomavirus (HPV) tests that are conducted in clinics and hospitals. (There are aspects of privacy and convenience issues for women to get these tests done on a regular basis, which accounts for late detection or inadequate detection frequency).
Current brands in the market, though only able to conduct either the Pap or HPV tests, whereas our product, the Cervisafe is aimed at conducting both tests in one kit. In addition currently, tests have to be conducted via appointments with clinics or hospitals.

Barriers towards Pap Smears

Lack of information
Think it is not important
Embarrassment and fear
Availability of female doctors
Don’t have time
Painful

_{(Source: Al Naggar, 2012. Barriers towards Pap smear test from a public hospital in Malaysia)}

Our Solution

Cervisafe is a 'Do-it-Yourself' Kit that caters for 'Privacy and Convenience - use at home', to test for both Pap and HPV.
The device extracts cell samples for both Pap and HPV tests at the convenience and privacy of user's home. In future, the test kit will be able to provide initial prognosis of conditions that can be followed up with a more detailed analysis at clinics or hospitals.

Advantages:

The product allows users to easily undertake her own cervical cell collection in the privacy of her home at their own time;
Users can perform the procedure in less than ten minutes
Kits will be readily available in pharmacies, clinic, hospitals, diagnostic centres and on-line platform;
Product covers both Pap and HPV tests.

LaDIY How It Works

Why Are We Different

Cervisafe

The unique design of the flower probe and material used allows sufficient cell sampling, to conduct both the Pap tests and the HPV tests (as compared to most products in the market) resulting in higher accuracy in diagnosis (>90%).

The patented tubular design and flower probe material allows for a smooth, non-traumatic entry thereby making the cell collection simple, comfortable, and easy to perform.

Our Revenue Model

Sale of Cervisafe Kits including laboratory analysis results

To direct on-line customers and via distribution channels such as pharmacies and outpatient clinics at RM300 per unit

Our Market Opportunity

The worldwide In-Vitro Diagnostics (IVD) Market is estimated @ RM 310 billion in 2016 & is forecasted to reach RM 402.3 billion by 2021, growing at a CAGR of 5.35% .

IVD plays a major role in the early diagnosis and management of diseases. The point of care testing segment is growing at a good pace in the IVD market. The US and Europe currently dominate the market owing to their increasing healthcare expenditure and improved clinical laboratory infrastructure. The United States market accounts for RM 104 billion market revenue, contributing to around 35% of the worldwide IVD market. here could be a rise in the IVD market share from the emerging economies as well, as diagnostic companies are focusing on capitalising on the untapped markets in the medical sector.

Our potential achievable market is estimated at RM 118 million, primarily targeting the ASEAN countries (with the following potential breakdown):

Country	Women (age>30) Eligible for Cx Cancer Screening	Target Market @1%	Projected Sales (RM)
Malaysia	10 Million	100,000	20 Million*
Vietnam	35 Million	350,000	17.5 Million**
Indonesia	100 Million	1,000,000	50 Million
Philippines	40 Million	400,000	20 Million
Thailand	20 Million	200,000	10 Million
Total	205 Million	2,050,000 tests/year	RM117.5 Million/year

*In Malaysia, price for Cervisafe Kit + Lab starts from RM200

**Outside of Malaysia, price for Cervisafe Kit only is RM50

Our Traction

Supported by Ministry of Science and Technology, we carried out CSR Cervical Awareness Programmes across Malaysia from 2016 to 2018. 1,000 Cervisafe units deployed & 700 patients screened.

Our Strategy

Marketing

In the short term, we will undertake a Market Penetration Exercise and Market Development Exercise. We plan to intensify our marketing efforts in Malaysia and develop the regional markets (with focus in Indonesia).
We will leverage on our marketing network and technology know-how, to develop our market through strategic partnership, maximising market penetration and product acceptance.
In addition, resources will be deployed in promotional campaigns, especially in its marketing communications mix plan.
Marketing mix communications strategy will include both the online media and the more traditional offline media campaigns. The overall intent is to create and reinforce awareness of LaDIY's brand name as well as the products Cervisafe™, Cervisafe II and AZYCare™; with a single global message to consistently drive the value proposition of these brands.

Regional Expansion

The immediate plan is to execute the commercialisation of Cervisafe™ with Malaysia as our primary target market (with an anticipated 25,000 units of Cervisafe™ being sold in Year 1).
Year 2 - Indonesia
Year 2 & 3 - ASEAN
Long term - China, Africa, US

Product Development

Development of AZYCare™

A customised digital app to accompany our Cervisafe™ do-it-yourself (DIY) test
AZYCare™ allows consumers (Cervisafe™ users), laboratory service providers (and suppliers) to seamlessly perform sample tracking, payment transaction, diagnosis (test results) and physician consultation over a secured encrypted platform.
AZYCare™ is developed with patient and healthcare provider convenience into consideration. It is designed to enhance the utility of home self-test kits, and to vastly increase accessibility to cervical cancer screening. Using a simple user friendly digital application, AZYCare™ creates a self-contained management tool for home self-testing use.

Development of Cervisafe II

Development of Cervisafe II to help improve cervical cancer screening (especially in developing countries), for onsite cervical cancer screening and treatment.
It is a single-use, user-friendly technology utilising key protein biomarkers that are sensitive and specific to cervical precancerous lesions. This innovation is advantageous in that it can detect at picogram levels, is colorimetry-based, easy to use (no need for highly trained personnel), rapid, highly sensitive, quantitative, highly affordable, and can be used independently or integrated into existing platforms, making this beneficial for use in developing countries for the screening of cervical cancer.

Product Diversification

The company is also planning to establish its own diagnostic laboratory services with the aim to position itself as a one-stop medical diagnostic solution provider.

Our Achievements

Indicative Usage of Funds

The breakdown for the RM 3 million fund utilisation will be as follows:

LaDIY Use of Funds

The Team

Romli Ishak

Chief Executive Officer

Onn B. Abu Bakar

Chief Operating Officer

Prof. Dato’ Dr. Mohamad Abdul Razak

Advisor

Dr. Kuan Chee Sian

Chief Technology Officer

Term Sheet

Issuer: LaDIY Healthcare Sdn Bhd, a private limited company incorporated in Malaysia, a private limited company incorporated in Malaysia

Type of Equity: Ordinary Shares (“Shares”)

Fund Raising Period: 90 days

Pre Money Valuation: RM25,000,000

Minimum Fundraising Target: RM 1,000,000

Maximum Fundraising Target: RM 2,000,000

Price per Share: RM 2500.00

Minimum Equity Offered: 3.85%

Maximum Equity Offered: 7.41%

Minimum Shares Offered: 800

Maximum Shares Offered: 1200

Minimum Investment Amount: RM 2,500

Rewards: Investment Amount

RM 2,500.00

Reward(s)

For every RM 2,500.00 investment, investor receives FREE 2 pcs of Cervisafe Kits; THIS DOES NOT INCLUDE LAB SERVICES OF RM 200.00 (per lab test).

Investment Amount

Rm 5,000.00

Reward(s)

For every RM 5,000.00 investment, investor receives FREE 4 pcs of Cervisafe Kits; THIS DOES NOT INCLUDE LAB SERVICES OF RM 200.00 (per lab test).

Investment Amount

RM 20,000.00

Reward(s)

For every RM 20,000.00 investment, investor receives FREE 20 pcs of Cervisafe Kits; THIS DOES NOT INCLUDE LAB SERVICES OF RM 200.00 (per lab test).

Investment Amount

RM 25,000 & above

Reward(s)

For every RM 25,000.00 investment, investor receives FREE 25 pcs of Cervisafe Kits; THIS DOES NOT INCLUDE LAB SERVICES OF RM 200.00 (per lab test).

Impact on Shareholding Structure Upon Completion of the Offering

Investor Eligibility: Retail, Angel, Sophisticated, and/or Institutional Investors, subject to the applicable investment limits prescribed under the Securities Commission’s Guidelines on Recognised Markets.

Pre Emptive Rights

Type of Shares

Information: Issuer to provide additional information upon request

Closing Period: 14 working days after the end of the Fundraising Period.

Use of Proceeds: The proceeds will be used for production of Cervisafe, marketing, Development of Cervisafe II, development of AzyCare, regulatory processes in Indonesia and China, and working capital

Subscription Procedure: An Investment Agreement to subscribe ordinary shares and subject to review if required or necessary, the procedure may be amended by the Issuer and the ECF Platform.

Disclaimer: The information, calculations and remarks expressed on this term sheet or on any other part of the platform are based on information provided, disclosed and presented by LaDIY Healthcare Sdn. Bhd. to Ata Plus Sdn. Bhd. either in part or in whole. Ata Plus disclaims responsibility for the accuracy, completeness and/or validity of these information, and hence will not be held liable for any inaccurate, inappropriate or incomplete information presented on this term sheet or on any other part of the platform subject to the following :
The financial information listed on the deal page is provided by the Issuer; which includes the financial forecasts and projections, the capitalization table, the term sheet, and management accounts.
The financial forecasts and projections have been prepared by the issuer based on assumptions that have not been reviewed and certified by an independent certified accountant for its reasonableness.
THE ISSUER agrees that; all information concerning the product, business and the assets of THE ISSUER that have been furnished to Ata Plus Sdn Bhd for the purpose of the equity crowdfunding campaign is true, complete, and accurate in all material respect and is not misleading or deceptive whether by inclusion or omission.
Should the Investor require more information, they can do so by contacting LaDIY directly at [email protected] or by clicking on the ‘CONTACT’ button on the Deals Page.

Disclosure: This issuer is referred by a 3rd party which is . Ata Plus is not associated or related to the issuer and the referral party.

Disclaimer by Securities Commission

(i) No shares will be alotted or issued based on this document after six months from the closing of the offer period

(ii) This issue, offer or invitation for the offering is a proposal not requiring authorisation of the Securities Commission under section 212(8) of the CMSA 2007

(iii) This document has not been reviewed by the Securities Commission Malaysia. The Securities Commission does not recommend nor assumes responsibility for any information including any statement, opinion or report disclosed in relation to this fund raising exercise and makes no representation as to its accuracy or completeness. The Securities Commission expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the information disclosed.

Issuer	LaDIY Healthcare Sdn Bhd, a private limited company incorporated in Malaysia
Type of Equity	Ordinary Shares (“Shares”)
Fund Raising Period	90 days
Pre Money Valuation	RM25,000,000
Minimum Fundraising Target	RM 1,000,000
Maximum Fundraising Target	RM 2,000,000
Price per Share	RM 2500.00
Minimum Equity Offered	3.85%
Maximum Equity Offered	7.41%
Minimum Shares Offered	800
Maximum Shares Offered	1200
Minimum Investment Amount	RM 2,500
Rewards	Investment Amount RM 2,500.00 Reward(s) For every RM 2,500.00 investment, investor receives FREE 2 pcs of Cervisafe Kits; THIS DOES NOT INCLUDE LAB SERVICES OF RM 200.00 (per lab test). Investment Amount Rm 5,000.00 Reward(s) For every RM 5,000.00 investment, investor receives FREE 4 pcs of Cervisafe Kits; THIS DOES NOT INCLUDE LAB SERVICES OF RM 200.00 (per lab test). Investment Amount RM 20,000.00 Reward(s) For every RM 20,000.00 investment, investor receives FREE 20 pcs of Cervisafe Kits; THIS DOES NOT INCLUDE LAB SERVICES OF RM 200.00 (per lab test). Investment Amount RM 25,000 & above Reward(s) For every RM 25,000.00 investment, investor receives FREE 25 pcs of Cervisafe Kits; THIS DOES NOT INCLUDE LAB SERVICES OF RM 200.00 (per lab test).
Investor Eligibility	Retail, Angel, Sophisticated, and/or Institutional Investors, subject to the applicable investment limits prescribed under the Securities Commission’s Guidelines on Recognised Markets.
Information	Issuer to provide additional information upon request
Closing Period	14 working days after the end of the Fundraising Period.
Use of Proceeds	The proceeds will be used for production of Cervisafe, marketing, Development of Cervisafe II, development of AzyCare, regulatory processes in Indonesia and China, and working capital
Subscription Procedure	An Investment Agreement to subscribe ordinary shares and subject to review if required or necessary, the procedure may be amended by the Issuer and the ECF Platform.
Disclaimer	The information, calculations and remarks expressed on this term sheet or on any other part of the platform are based on information provided, disclosed and presented by LaDIY Healthcare Sdn. Bhd. to Ata Plus Sdn. Bhd. either in part or in whole. Ata Plus disclaims responsibility for the accuracy, completeness and/or validity of these information, and hence will not be held liable for any inaccurate, inappropriate or incomplete information presented on this term sheet or on any other part of the platform subject to the following : The financial information listed on the deal page is provided by the Issuer; which includes the financial forecasts and projections, the capitalization table, the term sheet, and management accounts. The financial forecasts and projections have been prepared by the issuer based on assumptions that have not been reviewed and certified by an independent certified accountant for its reasonableness. THE ISSUER agrees that; all information concerning the product, business and the assets of THE ISSUER that have been furnished to Ata Plus Sdn Bhd for the purpose of the equity crowdfunding campaign is true, complete, and accurate in all material respect and is not misleading or deceptive whether by inclusion or omission. Should the Investor require more information, they can do so by contacting LaDIY directly at [email protected] or by clicking on the ‘CONTACT’ button on the Deals Page.
Disclaimer by Securities Commission	(i) No shares will be alotted or issued based on this document after six months from the closing of the offer period (ii) This issue, offer or invitation for the offering is a proposal not requiring authorisation of the Securities Commission under section 212(8) of the CMSA 2007 (iii) This document has not been reviewed by the Securities Commission Malaysia. The Securities Commission does not recommend nor assumes responsibility for any information including any statement, opinion or report disclosed in relation to this fund raising exercise and makes no representation as to its accuracy or completeness. The Securities Commission expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the information disclosed.

Risk Disclaimer

Investing in equity crowdfunding involves certain risks that include uncertainty of returns, lack of liquidity, dilution, material events and lack of control. Investments should be done as part of a diversiﬁed portfolio. ATA PLUS offers investment opportunities to investors who understands these risks in making their own investment decisions.

PLEASE READ THE FULL RISK WARNING BEFORE DECIDING TO INVEST.

This page is approved as a ﬁnancial promotion by ATA PLUS Sdn. Bhd., which is authorized and regulated by the Security Commission of Malaysia. Deals that are up for investment are only offered to members of ata-plus.com on the basis of information provided by the companies concerned. ATA PLUS takes no responsibility for this information or for any recommendations or opinions made by the companies. For further information on this, please read our Term of Use.